Pharma Journalist -

Artizan Biosciences, Inc. (“Artizan”), a biotechnology company creating gut exclusive microbial metalloprotease inhibitors (GEMMi), a new class of transformative precision therapeutics…
Read More...

Valneva SE announces that the European Commission (EC) has approved an amendment to the Advance Purchase Agreement (APA) it signed in November 2021 for Valneva’s inactivated whole-virus…
Read More...

CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy protein expression, announced the closing of a $100 million Series B round to advance the…
Read More...

AstraZeneca is supplying Switzerland with approximately 1,200 doses of tixagevimab and cilgavimab, a long-acting combination antibody therapy, for the treatment of COVID-19. The Swiss…
Read More...

Karyopharm Therapeutics Inc. announced new regulatory designations for eltanexor, a novel oral, Selective Inhibitor of Nuclear Export (SINE) investigational compound being studied for…
Read More...

ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop product candidates that address…
Read More...

SAE Media Group reports: Leading experts from big pharma will be presenting case studies on advances in drug delivery devices on the Pre-filled Syringes San Francisco Conference, this…
Read More...

Sorrento Therapeutics, Inc. announced the FDA clearance of a Phase 1 study of its oral main viral protease (Mpro) inhibitor, STI-1558, in patients with impaired renal and hepatic…
Read More...

Avista Therapeutics, which recently launched as a spinout of leading health system UPMC, aims to develop innovative gene therapies for rare ophthalmic conditions. The new company…
Read More...

Gilead Sciences and the European Commission signed a new joint procurement agreement (JPA) that will ensure continued rapid and equitable access to Veklury (remdesivir) for…
Read More...